对帕金森病患者进行昼夜有效光疗的双盲对照试验
Bradley T Wyman1, Dan Adams2, Suzanne Hendrix3
1OThree Consulting LLC, 1759 E Longbranch Ct, Draper, UT, 84020, USA.
概括
循环有效光疗 (CELT) 在帕金森病 (PD) 患者中显示出改善运动和非运动症状的趋势. 这种耐受性良好的治疗需要在更大的PD临床试验中进行进一步的研究.
科学领域:
- 神经学
- 时间生物学
- 光生物学
背景情况:
- 帕金森病 (PD) 呈现持续的运动和非运动症状,尽管目前的治疗方法.
- 光疗 (LT) 在治疗PD的运动和非运动特征方面表现出潜力.
研究的目的:
- 评估循环有效光疗 (CELT) 的疗效,使用特定的光谱频段 (460-545 nm),用于帕金森病患者的运动和非运动症状.
主要方法:
- 一个多中心,随机,双盲,受控试验,涉及92名帕金森病患者接受标准治疗.
- 在6个月的时间里,参与者被随机分配到每天接受1小时的活性CELT或控制CELT.
- 在"ON状态"中进行了评估,评估了包括MDS-UPDRS,PDQ-39,CGI和PDSS-2在内的初级和二级终点.
主要成果:
- 主要终点 (MDS- UPDRS部分1- 3) 显示活跃CELT组的改善趋势 (-17. 7) 与对照组的改善趋势 (- 9. 7),差异为- 8. 0 (p=0. 074).
- 主要的二次终点有利于积极治疗:PDQ-39 (- 5. 7 ± 2. 7; p=0. 038) 和CGI (- 0. 4 ± 0. 2; p=0. 066).
- CELT的耐受性很好,没有严重的不良反应,并得到ESS和CGI- E等二次终点的支持,表明整体治疗效果.
结论:
- 每日循环有效光疗 (CELT) 显示了帕金森病患者运动和非运动症状的改善趋势.
- 治疗耐受性良好,对生活质量和总体印象得分产生积极影响.
- 建议进行更大的双盲研究,以进一步验证CELT对帕金森病的有效性.
相关概念视频
01:24Parkinson's Disease: Treatment
376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
123
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
123
01:15Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702